Other Anterior Pituitary Tumors

Slide 1 · Other Anterior Pituitary Tumors

Lineage • Hormonal phenotype • Morphology • Clinical consequences

Pathology lecture

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning outcomes

Classify the less common anterior pituitary tumors by lineage and hormone expression.

Explain why hormonally silent tumors often present with mass effects and hypopituitarism.

Distinguish gonadotroph, thyrotroph, plurihormonal, null-cell, metastatic tumors and pituitary blastoma.

Apply morphology, immunophenotype, clinical features and metastatic status to diagnostic reasoning.

Slide 3 · The entities covered in this lecture

Gonadotroph

PitNET

Thyrotroph

PitNET

Plurihormonal

PitNET

Null-cell

PitNET

Also considered separately: Metastatic PitNET and DICER1-associated pituitary blastoma.

Slide 4 · Anterior pituitary tumor classification

PitNETs are categorized by hormone expression and cell lineage–associated transcription factors.

A tissue-positive hormone stain does not necessarily imply a clinically functioning tumor.

Some tumors express multiple hormones; Genuinely null-cell tumors lack lineage and hormone markers.

Metastatic status is a separate behavioral designation rather than another secretory lineage.

Slide 5 · Three dimensions of every PitNET

Lineage identity

IHC transcription factors

Hormone production

Tissue and/or serum

Clinical behavior

Hormone excess or mass effect

Clinical function, tissue phenotype and extent of disease must be assessed independently.

Slide 6 · Normal anterior pituitary cell functions

Cell lineage

Hormone(s)

Target or physiologic role

Gonadotroph

FSH, LH

Gonadal function

Thyrotroph

TSH

Thyroid hormone production

Corticotroph

ACTH

Adrenal cortex

Somatotroph

GH

Growth and IGF-1 axis

Lactotroph

PRL

Lactation

Slide 7 · The gonadal endocrine axis

Hypothalamus

GnRH

Pituitary

Gonadotroph

FSH / LH

Ovary or testis

Impaired gonadotropin secretion can result in gonadal endocrine dysfunction.

Slide 8 · The thyroid endocrine axis

Hypothalamus

TRH

Pituitary

Thyrotroph

TSH secretion

Thyroid hormone

A TSH-producing tumor can cause pituitary-driven hyperthyroidism.

Slide 9 · Three routes to clinical presentation

Hormone excess

A secretory tumor stimulates its target organ.

Thyrotroph PitNET: Hyperthyroidism.

Mass effect

Expanding lesion affects optic pathways and other local structures.

Headache, field loss or diplopia.

Hormone deficiency

Compression compromises normal pituitary tissue.

Gonadal and other target-organ dysfunction.

A tumor may produce more than one of these clinical consequences.

Slide 10 · Silent does not mean marker-negative

A silent PitNET may express a pituitary hormone or lineage factor by immunohistochemistry.

Despite this expression, the patient does not develop the expected hormone-excess syndrome.

A null-cell PitNET has neither convincing hormonal differentiation nor lineage-marker expression.

Both may present with headache, visual disturbance and pituitary hormone deficiencies.

Slide 11 · PitNET architecture is distinct from normal pituitary

Normal anterior pituitary — schematic

PitNET — schematic

Mixed cell populations; Preserved stromal network

Relatively monomorphic cells; Sparse reticulin

Slide 12 · Morphologic hallmarks of a typical PitNET

Tumors often appear soft and well circumscribed within the sella turcica.

Histology shows relatively uniform polygonal cells arranged in sheets or cords.

The supporting reticulin framework is sparse compared with normal anterior pituitary.

Immunostaining establishes hormone and transcription-factor phenotype.

Slide 13 · Local growth can threaten visual function

Intrasellar

PitNET growth

Suprasellar

Extension

Optic chiasm

Compression

Visual field

Abnormality

The classic chiasmal pattern is bitemporal hemianopia.

Slide 14 · Sellar mass effects may dominate the presentation

Expansion may cause headache and compress the optic chiasm, producing temporal visual field defects.

Invasion or extension toward adjacent structures can be accompanied by diplopia.

Nonfunctioning tumors often enlarge before detection because endocrine symptoms are absent.

The anatomical burden of disease may be more conspicuous than its secretory phenotype.

Slide 15 · Destructive expansion leads to hypopituitarism

Growing sellar lesion

Compression of

Normal adenohypophysis

Reduced trophic

Hormone output

Peripheral endocrine

Deficiency

Hypopituitarism may accompany a nonfunctioning PitNET even when the tumor itself has no secretory syndrome.

Slide 16 · Pituitary apoplexy: An acute deterioration

Intratumoral

Hemorrhage

Rapid sellar

Enlargement

Neural compression +

Pituitary failure

Acute clinical

Emergency

Sudden severe headache, visual or ocular-motor symptoms and adrenal insufficiency require urgent assessment.

Slide 17 · Why gonadotroph PitNETs can be overlooked

Gonadotroph tumors synthesize gonadotropin-related proteins but usually cause no recognizable hormone-excess syndrome.

Only small amounts of hormones may be secreted into the circulation.

Most behave clinically as nonfunctioning lesions until local effects become apparent.

The absence of a classic endocrine syndrome should not be mistaken for absent cell differentiation.

Slide 18 · Gonadotroph PitNET: Usual presentation

The typical clinical setting is a middle-aged adult with a sellar lesion.

Visual impairment and headaches reflect an expanding mass.

Diplopia may arise when local extension affects ocular motor pathways.

Pituitary apoplexy can bring an otherwise unrecognized lesion to attention abruptly.

Slide 19 · How a gonadotroph tumor causes sexual symptoms

Gonadotroph

PitNET expands

Normal gonadotroph

Function impaired

LH output

Falls

Hypogonadal

Manifestations

The clinical hypogonadism can reflect reduced normal LH secretion, not an LH excess syndrome.

Slide 20 · Gonadotroph tumors in men

Compression of the nonneoplastic anterior pituitary can reduce LH secretion.

Insufficient LH stimulation results in reduced testicular testosterone production.

Clinical correlates in the source include decreased energy and libido.

These findings may coexist with headache or visual field abnormalities.

Slide 21 · Gonadotroph tumors in women

Loss of normal pituitary LH secretion disrupts ovarian endocrine function.

Amenorrhea is a recognized presentation in premenopausal patients.

Visual disturbances and headaches may provide the clue to an underlying sellar lesion.

Absence of a hypergonadotropic syndrome does not exclude a gonadotroph lineage.

Slide 22 · Gonadotropins comprise shared and specific subunits

Common α-subunit

FSH β-subunit

LH β-subunit

FSH-associated tumor phenotype

LH-associated tumor phenotype

Schematic • FSH is described as the predominant secreted hormone.

Slide 23 · Immunophenotype of gonadotroph PitNET

Tumor cells can express the common gonadotropin α-subunit.

Immunoreactivity for FSH-β and/or LH-β supports gonadotropin differentiation.

Steroidogenic factor-1 (SF-1) is an important lineage-associated nuclear factor.

Estrogen receptor α (ERα) is also associated with gonadotroph differentiation in the supplied discussion.

Slide 24 · Diagnostic distinction: Hormone versus lineage

IHC for FSH / LH

(hormonal identity)

IHC for SF-1

(lineage identity)

Correlate with hormone

Excess syndrome

Classify PitNET

Phenotype

Lineage markers can classify a clinically silent tumor when serum hormone excess is absent.

Slide 25 · What is and is not established by hormone staining

What it establishes

Expression of a protein within neoplastic cells.

Support for lineage-specific differentiation.

A basis for histologic classification.

What it does not establish

A clinically significant secretory syndrome.

The degree of serum hormone elevation.

That the tumor is confined or metastatic.

A nonfunctioning PitNET may be IHC-positive for a specific hormone.

Slide 26 · Case: A hormonally silent sellar mass

Hypothetical: A middle-aged patient has progressive peripheral visual loss and reduced libido. A sellar tumor lacks a clinically recognizable hormone-excess syndrome.

Interpretation

Which pituitary lineage is common in this type of presentation?

Why can libido fall when the tumor is not actively secreting excess LH?

Which tissue markers would help establish the lineage?

Slide 27 · Thyrotroph PitNET: A rare functional tumor

Thyrotroph PitNETs synthesize thyroid-stimulating hormone (TSH).

They are uncommon, accounting for approximately 1% of PitNETs in the supplied source.

They can drive thyroid hormone overproduction and are a rare cause of hyperthyroidism.

Their identity must be considered in the context of the normal hypothalamic–pituitary–thyroid axis.

Slide 28 · How TSH excess produces hyperthyroidism

TSH-producing

PitNET

Increased thyroid

Stimulation

Thyroid hormone

Production

Hyperthyroid

State

The initiating lesion is in the pituitary rather than in the thyroid gland.

Slide 29 · Central versus primary thyroid pathology

In thyrotroph PitNET, abnormal pituitary TSH secretion can stimulate the thyroid.

The resulting hyperthyroidism does not establish an autonomous primary thyroid disorder.

Tumor lineage, thyroid hormone findings and the direction of endocrine drive must be considered together.

The supplied section does not specify numerical thresholds or a formal biochemical testing algorithm.

Slide 30 · Thyrotroph lineage is shared with other PIT1 tumors

POU1F1 (PIT1)

Lineage identity

Thyrotroph

TSH

Somatotroph

GH

Lactotroph

PRL

The shared transcription-factor lineage does not make these tumors hormonally equivalent.

Slide 31 · Comparison within the PIT1 lineage

Lineage phenotype

Dominant hormone

Characteristic endocrine effect

Thyrotroph PitNET

TSH

Hyperthyroidism

Somatotroph PitNET

GH

Acromegaly / gigantism

Lactotroph PitNET

PRL

Reproductive dysfunction / galactorrhea

Some plurihormonal PitNETs

GH, PRL, TSH

Multiple hormone expression

Slide 32 · Interpreting an apparent TSH-producing lesion

First identify the patient's endocrine phenotype and the nature of the sellar mass.

Demonstrate TSH expression in the tumor and assess its PIT1-lineage phenotype.

Differentiate tumor-derived hormone excess from secondary endocrine disturbances caused by tissue compression.

Do not equate TSH immunopositivity alone with clinically manifest hyperthyroidism.

Slide 33 · Case: Hyperthyroidism with a sellar tumor

Hypothetical: An adult presents with clinical hyperthyroidism. Imaging shows a pituitary mass, and tumor cells are immunoreactive for TSH.

Interpretation

What lineage is suggested by the tumor hormone?

Which transcription factor family supports the lineage?

Why must tissue hormone expression be correlated with clinical endocrine findings?

Slide 34 · Plurihormonal PitNETs: The key distinction

Some PitNETs express or secrete more than one pituitary hormone.

The source highlights GH and PRL as a frequent combination in double-hormone pituitary tumors.

Table 24.1 includes a plurihormonal phenotype with GH, PRL and TSH expression.

Hormone multiplicity must be interpreted alongside cell-lineage and cell-distribution findings.

Slide 35 · Two patterns of multiple-hormone expression

Bihormonal tumor cell

Mixed populations

GH + PRL

GH + PRL

GH + PRL

GH + PRL

GH + PRL

GH + PRL

GH

PRL

GH

PRL

GH

PRL

Same neoplastic cells express both hormones

Different cell groups express different hormones

Slide 36 · Cell-level hormone mapping matters

A single cell that expresses GH and PRL differs conceptually from a tumor containing distinct GH-positive and PRL-positive populations.

The adjacent somatotroph section explicitly distinguishes mammosomatotroph from mixed somatotroph–lactotroph PitNET.

The phenotype of a plurihormonal lesion cannot always be inferred from one bulk positive stain.

Cell distribution and lineage markers contribute to precise classification.

Slide 37 · Behavior of plurihormonal PitNETs

The supplied section describes plurihormonal tumors as usually aggressive.

This is a qualitative description, not a quantified risk or an individually predictive rule.

Aggressive local behavior must not be equated with the presence of metastasis.

Clinical course, tissue differentiation and disease extent remain distinct assessments.

Slide 38 · Null-cell PitNET: A stringent diagnosis

A null-cell PitNET lacks detectable markers of pituitary hormonal differentiation.

It also lacks convincing immunophenotypic evidence of the recognized pituitary cell lineages.

A clinically silent tumor with demonstrable SF-1 or PIT1 expression is therefore not null by definition.

The label should not be applied merely because endocrine symptoms are absent.

Slide 39 · Silent PitNET versus null-cell PitNET

Diagnostic feature

Silent lineage-defined PitNET

Null-cell PitNET

Hormone-excess syndrome

Absent

Absent

Tissue hormone expression

Can be present

Absent by definition

Lineage factor

Can be present

Absent by definition

Typical clinical problem

Mass effect ± deficiency

Mass effect ± deficiency

Slide 40 · Why null-cell tumors produce local symptoms

A null-cell PitNET has no defining hormonal hypersecretion syndrome.

Its expanding volume can compromise optic pathways and other local structures.

It may also compress residual anterior pituitary and reduce normal endocrine output.

The clinical burden reflects mass and gland destruction rather than tumor hormone secretion.

Slide 41 · Progressive null-cell tumor: Dual consequences

Nonfunctioning PitNET growth

Optic compression → visual symptoms

Pituitary compression → hypopituitarism

Distinct effects can coexist: Local neurologic dysfunction and trophic-hormone deficiency.

Slide 42 · Acute versus gradual gland failure

Gradual null-cell tumor expansion can progressively impair pituitary function.

Hemorrhage into the tumor can produce abrupt enlargement and acute endocrine failure.

Acute corticotropin deficiency may cause adrenal insufficiency and hemodynamic deterioration.

Recognizing possible apoplexy matters even when a lesion has no known hormonal activity.

Slide 43 · A tissue workup for clinically nonfunctioning PitNET

Morphology suggests

PitNET

Lineage IHC

PIT1 / SF-1 / TPIT

Hormone IHC

GH / PRL / TSH / FSH / LH / ACTH

Assign lineage or

Consider null cell

This is a conceptual classification pathway, not a complete clinical laboratory protocol.

Slide 44 · Metastatic PitNET: Definition is anatomical

Metastatic PitNETs were formerly called pituitary carcinomas.

The decisive criterion is documented craniospinal or systemic metastasis.

Invasion of nearby dura, cavernous sinus or bone alone does not satisfy this metastatic definition.

Metastatic behavior is established by spread, not inferred solely from atypia or local size.

Slide 45 · Local invasion is not the same as metastasis

Primary PitNET in sella

Contiguous invasion of adjacent structures

Separate craniospinal or systemic deposits

Local invasion: Not sufficient

Metastatic disease: Required criterion

Slide 46 · Metastatic PitNET: Frequency and timing

The source reports metastatic PitNETs in fewer than 1% of pituitary tumors.

Metastases tend to appear late in the disease course.

Many affected patients have had multiple episodes of local tumor recurrence.

The presence of recurrences raises concern but does not itself demonstrate metastatic spread.

Slide 47 · A typical sequence before metastasis

Initial localized

PitNET

Local tumor

Recurrence

Additional local

Recurrence(s)

Late craniospinal or

Systemic metastasis

Schematic represents a frequently described course, not a predetermined natural history.

Slide 48 · Hormonal activity in metastatic PitNET

Most metastatic PitNETs are described as hormonally functional.

Prolactin and corticotropin are the most commonly secreted products in the source.

Secretory phenotype and metastatic designation answer different diagnostic questions.

Hormone staining cannot replace anatomic proof of a craniospinal or systemic metastasis.

Slide 49 · Case: Recurrence versus metastatic disease

Hypothetical: A PitNET has recurred locally after treatment and invades an adjacent cavernous sinus. No separate lesion has been established.

Interpretation

Does local recurrence and invasion meet the metastatic definition?

What new finding would change the designation to metastatic PitNET?

Which endocrine lineages are often functioning in metastatic PitNET?

Slide 50 · Pituitary blastoma: A distinctive pediatric entity

Pituitary blastoma is not simply a conventional adult PitNET presenting in childhood.

The source places typical presentation before 2 years of age.

It is associated with germline DICER1 mutations.

The diagnosis combines developmental-type morphology, endocrine manifestations and hereditary context.

Slide 51 · DICER1 and microRNA biology

Germline DICER1

Pathogenic variant

Impaired microRNA-

Processing pathway

Predisposition to

Embryonal tumors

Pituitary blastoma

Phenotype

DICER1 links the pituitary tumor to a broader inherited tumor-predisposition context.

Slide 52 · Microscopic appearance of pituitary blastoma

The tumor contains immature blastema-like cellular components.

These include cells described as “small round blue cells.”

Rosette-like formations can resemble the primitive Rathke epithelium.

The morphology suggests an embryonal developmental phenotype rather than an ordinary differentiated PitNET.

Slide 53 · Primitive pituitary blastoma morphology — schematic

Immature blastema-like

Cell population

Rosette-like formations

Diagrammatic rosette motif • not a photomicrograph

Slide 54 · Pituitary blastoma and Cushing disease

Pituitary

Blastoma

Corticotropin-linked

Endocrine activity

Adrenal cortisol

Excess

Cushing disease

Manifestations

Cushing disease refers to pituitary-driven ACTH-dependent hypercortisolism.

Slide 55 · The DICER1 tumor-predisposition context

Pituitary blastoma is associated with a germline DICER1 alteration.

The source highlights primitive blastema-like tumors in other organs in these children.

Pleuropulmonary blastoma is specifically identified as a common associated neoplasm.

The genetic association provides information beyond local pituitary morphology.

Slide 56 · Pituitary blastoma versus conventional PitNET

Feature

Pituitary blastoma

Conventional PitNET

Usual clinical setting

Infant; often <2 years

Typically adult

Genetic association

Germline DICER1

Various somatic or inherited alterations

Morphology

Primitive blastema + rosettes

Relatively monomorphic polygonal cells

Characteristic clue

Cushing disease; associated blastomas

Hormonal phenotype or local effects

Slide 57 · Integrated tumor classification

Entity

Phenotype or marker

Characteristic presentation

Gonadotroph

FSH / LH; SF-1

Often silent; mass effect / hypogonadism

Thyrotroph

TSH; PIT1 lineage

Hyperthyroidism

Plurihormonal

Multiple pituitary hormones

Complex hormone phenotype; aggressive course noted

Null-cell

No hormone or lineage markers

Mass effect / hypopituitarism

Metastatic PitNET

Defining distant spread

Late craniospinal / systemic metastasis

Pituitary blastoma

DICER1; primitive morphology

Infancy; Cushing disease

Slide 58 · A practical diagnostic reasoning sequence

Endocrine phenotype

Function or silence

Anatomical extent

Local or metastasis

Cellular phenotype

Hormones + lineage IHC

Assign entity with

Clinical-pathologic fit

No single variable — hormone expression, size, or invasion — independently settles every diagnosis.

Slide 59 · Common interpretive pitfalls

Calling a tumor “null-cell” solely because no hormone-excess syndrome is present.

Assuming gonadotropin positivity guarantees a clinically functioning gonadotroph lesion.

Equating local invasion or repeated recurrence with documented metastasis.

Mistaking pituitary blastoma for a routine PitNET without considering age and DICER1.

Slide 60 · Synthesis case: Infantile Cushing disease

Hypothetical: An infant has signs of Cushing disease and a primitive pituitary lesion with small blue cells and rosette-like arrangements.

Interpretation

What tumor entity best integrates age, endocrine phenotype and morphology?

Which inherited genetic alteration is associated with it?

Which extracranial tumor association is identified in the source?

Slide 61 · Four concepts to retain

Hormone expression, clinically functioning status and tumor lineage are related but not synonymous.

Gonadotroph and null-cell PitNETs commonly enter care through mass effects and pituitary insufficiency.

The definition of metastatic PitNET requires anatomically separate spread.

Pituitary blastoma is an infantile, DICER1-associated embryonal tumor with Cushing disease presentation.

Slide 62 · Suggested pathology reporting framework

Record tumor morphology and any available reticulin or architectural observations.

Specify hormone immunostains and pituitary lineage-associated transcription factors.

Correlate immunophenotype with the clinical secretory syndrome or hormonally silent presentation.

Document local invasion and any proven craniospinal or systemic metastasis separately.

Slide 63 · Reference and source boundary

Robbins, Cotran & Kumar: Pathologic Basis of Disease, 11th edition (2026), Chapter 24: The Endocrine System.

Primary section: “Other Anterior Pituitary Tumors,” page 976; adjacent pituitary sections and Tables 24.1–24.2 for context.

For tumor lineage classification, review the pituitary hormone/transcription-factor comparison in Table 24.1.

For pituitary genetic associations, review the related molecular summary in Table 24.2.